Search company, investor...

Evrys Bio

Founded Year



Grant | Alive

Total Raised


Last Raised

$34.3M | 1 yr ago



About Evrys Bio

Evrys Bio aims to develop antivirals that are safe, address the problem of acquired drug resistance, and provide unique broad-spectrum treatment options. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the cell’s intrinsic immunity to defend against infection.

Headquarters Location

3805 Old Easton Road

Doylestown, Pennsylvania, 18902,

United States


Missing: Evrys Bio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Evrys Bio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Evrys Bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Evrys Bio is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Evrys Bio Patents

Evrys Bio has filed 6 patents.

The 3 most popular patent topics include:

  • Animal virology
  • Designer drugs
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Virology, Animal virology, Influenza, Animal viral diseases, Immunology


Application Date


Grant Date



Related Topics

Virology, Animal virology, Influenza, Animal viral diseases, Immunology



Latest Evrys Bio News

Escient Pharmaceuticals Announces $120 Million Series C Financing

Nov 28, 2022

Financing led by New Enterprise Associates (NEA), Abingworth and Forge Life Science Partners Proceeds support advancement of EP262 and EP547 to multiple clinical milestones November 28, 2022 12:00 AM Eastern Standard Time SAN DIEGO--( BUSINESS WIRE )--Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the closing of a $120 million Series C financing. The financing was co-led by NEA, Abingworth, and Forge Life Science Partners with participation from other new investors Avego, PFM Health Sciences, and The Eleven Fund, as well as the company’s existing investors The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners (OUP), and Altitude Life Science Ventures. Proceeds from the financing will be used to advance the company’s pipeline of two first-in-class product candidates in several indications. This includes clinical proof-of-concept studies for EP262 (MRGPRX2 antagonist) in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CindU) and atopic dermatitis (AD) and for EP547 (MRGPRX4 antagonist) in cholestatic pruritus. Escient’s initial focus is on a novel class of cell surface receptors called Mas-related G protein-coupled receptors, or MRGPRs. MRGPRs are chemosensory receptors expressed on sensory neurons and immune cells, which reside in close proximity to one another in key barrier tissues such as the skin, airways and gastrointestinal tract. MRGPRs mediate the neuro-immune overactivation that is a hallmark of numerous chronic disorders, including many allergic, inflammatory, auto-immune, pain and pruritic diseases. “By specifically blocking the activation of MRGPRX2 and MRGPRX4 with small molecule antagonists, we aim to develop effective oral medications with novel mechanisms of action for serious neurosensory-inflammatory diseases without the serious side effects observed with other approaches,” said Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals. “We are thrilled with the support from both existing and new investors, and this significant financing puts us in a great position to advance our pipeline to clinical proof-of-concept in multiple indications.” About Escient Pharmaceuticals Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders. The company’s pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus. Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors. Visit to learn more. Contacts

Evrys Bio Frequently Asked Questions (FAQ)

  • When was Evrys Bio founded?

    Evrys Bio was founded in 2012.

  • Where is Evrys Bio's headquarters?

    Evrys Bio's headquarters is located at 3805 Old Easton Road, Doylestown.

  • What is Evrys Bio's latest funding round?

    Evrys Bio's latest funding round is Grant.

  • How much did Evrys Bio raise?

    Evrys Bio raised a total of $37.87M.

  • Who are the investors of Evrys Bio?

    Investors of Evrys Bio include U.S. Department of Defense and Princeton University.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.